Go to deals
Healthcare

Chirana T. Injecta, a.s. has acquired Chirmax, s.r.o.

Chirana T. Injecta, a.s. has acquired a 100% stake in Chirmax, s.r.o., the Czech manufacturer of surgical suture material, for an undisclosed consideration.

Chirana T. Injecta, a.s. is a manufacturer of disposable medical devices.

Oaklins' team in the Czech Republic acted as financial advisor to the buyer in this transaction.

Parties

Talk to the deal team

Vladimír Jaros

Principal
Prague, Czech Republic
Oaklins WOOD & Co.

Michal Staron

Associate Partner
Bratislava, Slovakia
Oaklins WOOD & Co.

Related deals

Afric Phar has been acquired by Pharma Capital
Healthcare

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

Learn more
Xiel Limited has been acquired by MIS Healthcare
Private Equity | Healthcare

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Learn more
Bayer AG has entered into a takeover agreement with Cara Care
Healthcare | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Learn more